AN END-TO-END & SCALABLE DIGITAL PLATFORM DESIGNED FOR WEB-ASSISTED GENETIC COUNSELLING

Doron Behar, CEO, Igentify, Tirat Hacarmel, Israel

- **Investment Rational**
  An end-to-end & scalable digital platform designed for web-assisted genetic counselling.

- **Business Strategy**
  The company’s go-to-market strategy for following customer segments:
  - Near-term (1-2 years) – Technology providers
  - Mid-term (2-5 years) – DTC & Non-DTC companies
  - Long-term (>5 years) – Retail

- **Core Technology**
  Genetic Algorithms – carrier screening, risk assessments, variant prediction etc.
  Platform adaptive to various test types.
  Platform adaptive to various genotyping technologies – microarray, NGS, CMA etc.
  Easy, intuitive & user-engaging UI & UX capabilities - enables smooth end-to-end process.
  Uniqueness & Value Proposition – enable the GCs to attend minimum of 10X more patients.

- **Product Profile/Pipeline**
  Igentify’s platform has 4 modules:
  - Access – Powerful and intuitive process to enroll, consent and acquire necessary information from the patient
  - Analyze – Quickly analyze and annotate with our geneticist approved workflow.
  - Insight – Create actionable data, quick glance interpretation, and receive recommendations.
  - Counsel – Automatically generate actionable reports and deliver engaging and educational digital genetic reports in minutes.

- **What’s Next?**
  R&D – Expanding the capabilities of the developed platform to various test types & genotyping technologies.
  Preclinical / Clinicals – Igentify will conduct clinical trials for other test types in future too.